Cancer Vaccines: Hype, Hope, and Hard Science

“The good thing about science is that it’s true whether or not you believe in it.”
-Neil deGrasse Tyson

Introduction :

When news broke that Russia’s experimental cancer vaccine “EnteroMix” had achieved “100% efficacy” in early trials, it sent ripples across the scientific community and beyond. The bold claim dominated headlines, stirring both excitement and scepticism. Could a vaccine truly eliminate cancer, the world’s deadliest disease? Cancer, once considered an incurable disease, has long challenged scientists and clinicians due to the immense complexity of the human body. Each tumour behaves differently, carries a unique genetic fingerprint, adapts to evade immunity and spreads silently through the body. Cancer was seen as an incurable mystery, a relentless disease that reflected the complexity of the human body and the limits of medicine. Unlike infectious diseases, where a single vaccine can train the immune system to fight a virus or bacterium, cancer is far more elusive, and that's why, for decades, the idea of a “cancer vaccine” seemed impossible. But science has never stopped pushing those limits.

“We are at the dawn of a new era where the immune system will be harnessed to control and cure cancer,” remarked Nobel laureate James P. Allison, a pioneer of modern immunotherapy. His words resonate powerfully today, as the world watches new attempts to turn cancer from an incurable menace into a preventable and treatable condition. Nowhere is this hope more vividly illustrated than in Russia’s recent announcement of its experimental cancer vaccine, EnteroMix, with claims of “100% efficacy” in early studies. While experts and scientists urge caution, the evidence so far is mostly from preclinical studies and limited early trials. Yet, recent headlines have ignited hope worldwide. Around the globe, from the mRNA breakthroughs of Moderna and BioNTech to Japan’s approval of oncolytic virus therapy, researchers are racing to turn the dream of a cancer vaccine into reality. It was this mix of hope, controversy, and possibility that inspired me to explore the wider world of cancer vaccines. This article examines EnteroMix’s recent claims in the context of global innovations, comparing their scientific promise, challenges, and how innovations across the world are bringing us closer to rewriting cancer’s story.

EnteroMix :

In early September 2025, Russia grabbed international headlines after the Ministry of Health announced that its cancer vaccine, EnteroMix, was “ready for use,” claiming 100% efficacy and safety. The statement, delivered by Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), during the 10th Eastern Economic Forum (EEF) in Vladivostok (3–6 September), sparked intense global debate. Newspapers, scientific circles, and social media platforms worldwide lit up with both praise and scepticism. The Eastern Economic Forum is a prestigious annual event aimed at fostering investment in the Far East and enhancing Asia-Pacific cooperation. In 2025, it brought together over 8,400 delegates from 75 countries under the theme “The Far East: Cooperation for Peace and Prosperity.” Among more than 100 thematic sessions, it was EnteroMix that captured the spotlight. On September 7, Russian media outlet Sputnik announced X, quoting“ The Russian EnteroMix cancer vaccine is now ready for clinical use, the Federal Medical and Biological Agency (FMBA) has announced.” According to Skvortsova, the EnteroMix vaccine is personalised for each patient, designed using their unique RNA profile. The first version, awaiting approval, targets colorectal cancer, one of the deadliest and most widespread cancers globally. Preclinical trials demonstrated that the vaccine could significantly reduce tumour size and slow progression, while also proving safe for repeated administration. Research is also advancing on vaccine variants for glioblastoma, an aggressive brain tumour and certain melanomas, including ocular melanoma. Further investigation into the official website of Russia’s National Medical Research Radiological Centre (NMRRC) reveals that two types of vaccines are being developed.

Oncolytic Vaccine (EnteroMix):

This uses a combination of four non-pathogenic viruses engineered to directly destroy malignant cells while simultaneously activating innate immunity (the body’s first, non-specific line of defence). Preclinical studies reportedly confirmed its safety and efficacy. Developed by the NMRRC in collaboration with the Engelhardt Institute of Molecular Biology under the Russian Academy of Sciences, EnteroMix was publicly unveiled at the International Economic Forum (SPIEF 2025) as part of Russia’s biotech showcase. Phase 1 clinical trials began in June 2025 with 48 volunteers.

Personalized mRNA Vaccine:

This second approach works at the molecular level by programming the immune system to recognise and fight cancer cells based on each patient’s unique tumour mutations. Using specialised software, researchers create an individualised vaccine tailored to the genetic “portrait” of a tumour. This vaccine is still under development.

It is important to note that the vaccine being claimed as “safe and effective” at present is the oncolytic EnteroMix vaccine. Preclinical studies and early Phase 1 trials suggest encouraging results, such as tumour reduction and immune activation, but these findings are based on fewer than 50 participants. In modern medicine, such early-stage results cannot be considered conclusive. The pathway from discovery to clinical use of any drug or vaccine is long and rigorous. Typically, a new therapy must pass through four phases of clinical trials, involving thousands of patients, before gaining regulatory approval. Transparency and data are also very important factors. Even after approval, long-term monitoring of safety and adverse drug reactions (ADRs) continues. Russia’s bold claim of “100% efficacy and safety” at this stage, therefore, should be interpreted cautiously. While EnteroMix represents a potentially groundbreaking step in precision cancer therapy, the global scientific community agrees that there is still a long way to go before it can be considered a reliable, widely applicable treatment.

Beyond the Impossible :

Despite knowing that Russia’s claims of “100% efficacy and safety” are far from scientifically proven, the announcement created enormous hype. The very idea of a cancer vaccine taps into one of humanity’s deepest hopes, a cure for a disease that affects millions worldwide. Cancer has long been seen as a puzzle too complex to solve with a single intervention. So, whenever a breakthrough is announced, even at the earliest stages, it naturally sparks headlines, investment interest, and public imagination. Another factor behind this excitement is the example of COVID-19 vaccines. Traditionally, drug and vaccine development takes over a decade, with countless trials and regulatory hurdles. Yet the COVID-19 pandemic proved that science can move at unprecedented speed. Vaccines by Pfizer-BioNTech, Moderna, and Bharat Biotech were designed, tested, and rolled out in less than a year, saving millions of lives worldwide. This rapid success has reshaped public and scientific expectations. If vaccines against a brand-new virus could be developed so quickly and effectively, then perhaps cancer, too, can be tackled with bold new platforms. Moreover, Russia is not alone in this pursuit. The concept of cancer vaccines has been under development for years across the globe. From the HPV vaccine, which prevents cervical cancer, to experimental mRNA vaccines in the U.S. and Europe for melanoma, pancreatic, and lung cancers, the field is rapidly expanding. This momentum has carried into oncology, where researchers are now reimagining vaccines not just as tools for prevention, but as personalised weapons against existing tumours.

From COVID to Cancer: The mRNA Revolution Expands

The COVID-19 pandemic changed the world in countless ways, but for medicine, its greatest legacy may be the rapid validation of mRNA technology. Before 2020, vaccine development typically took 10–15 years, with long stretches of trial-and-error and expensive research pipelines. Yet within a year of SARS-CoV-2 being identified, scientists had designed, tested, and distributed the first mRNA vaccines. The Pfizer-BioNTech and Moderna vaccines showed not only remarkable safety and efficacy but also a new paradigm: vaccines could be designed at lightning speed by programming mRNA to carry instructions directly to the body’s cells.

This same blueprint is now being repurposed for one of humanity’s most formidable enemies. The limitations of traditional treatments such as surgery, chemotherapy, and radiation, the cornerstones of cancer care for decades, are powerful but flawed tools. Surgery may remove visible tumours, but cannot always capture microscopic disease. Radiation and chemotherapy, while effective at killing rapidly dividing cells, do so indiscriminately, often damaging healthy tissues and causing enormous side effects. Worse still, tumours are not static. They mutate, adapt, and develop resistance, rendering once-effective treatments powerless. Unlike infectious diseases, however, cancer poses unique challenges. Tumours are born from our own cells, making them difficult to distinguish from healthy tissue. Even cutting-edge immunotherapies like checkpoint inhibitors or CAR-T cells, though revolutionary, are not universally effective across all cancers.

This is where immunotherapy and especially cancer vaccines hold unique promise. Instead of fighting cancer from the outside with toxic weapons, they mobilise the body’s own defences, capable of adapting and remembering the enemy. In many ways, the dream of a cancer vaccine is the culmination of over a century of effort. To transform cancer from a relentless killer into a disease that the body itself can control. Here is where mRNA vaccines stand apart. By analysing the genetic profile of a patient’s tumour, researchers can identify neoantigens, mutations unique to that individual’s cancer. An mRNA vaccine is then designed to “teach” the immune system to recognise and attack cells carrying those neoantigens, leaving healthy cells untouched. Unlike traditional one-size-fits-all treatments, this approach is inherently personalised, offering precision and adaptability.

History of Immunotherapy:

The idea that the body’s own immune system could be turned against tumours is not new. It traces back more than a century. In the late 1800s, William Coley, often hailed as the father of immunotherapy, noticed that cancer patients who developed severe bacterial infections sometimes experienced dramatic tumour shrinkage. Inspired, he began injecting patients with mixtures of inactivated bacteria, now remembered as “Coley’s toxins.” Though crude and inconsistent, his work planted the first seed of cancer immunotherapy. By the mid-20th century, the concept of “immune surveillance” suggested that our immune system constantly patrols for abnormal cells, including cancer. Around this time, the discovery of cytokines (small proteins that act as messengers to facilitate communication between cells, particularly within the immune system), such as interferons and interleukins, hinted at new ways to harness the immune system’s natural messengers. This led to therapies like Interleukin-2 (IL-2) in the 1970s, which later became one of the first FDA-approved immunotherapies for advanced melanoma and kidney cancer. Interleukin-2 activates anti-cancer immune cells (T cells ) to fight tumours.

The 1990s biotechnology revolution opened another door. Scientists began engineering monoclonal antibodies that could precisely target proteins on cancer cells. Drugs like Rituximab for lymphoma proved that instead of indiscriminately killing cells as chemotherapy did, Rituximab could “tag” tumours for immune destruction. The 2010s introduced CAR-T cell therapy, where a patient’s own T-cells are genetically reprogrammed to act as living drugs. The approval of Kymriah in 2017 for childhood leukaemia symbolised not just a scientific triumph but the dawn of a new era in truly personalised medicine.

And now, in the 2020s, the story enters its boldest chapter yet. With the success of mRNA vaccines during COVID-19, scientists are racing to apply similar platforms to cancer. These personalised vaccines are designed to recognise the unique “mutation fingerprint” of an individual’s tumour, training the immune system to attack cancer cells with the precision of a sniper rather than the blunt force of chemotherapy. Russia’s EnteroMix, regardless of the controversies surrounding its early claims, is part of this global shift toward precision immunotherapy. The idea is no longer theoretical. In early clinical trials, BioNTech’s personalised mRNA vaccines for melanoma have significantly reduced relapse rates when combined with immunotherapy, while Moderna is exploring applications for lung and pancreatic cancers. Preventive vaccines already exist, too, such as the HPV vaccine, which has dramatically reduced cervical cancer rates worldwide, and the Hepatitis B vaccine, which protects against liver cancer. These successes prove that vaccines can be a powerful tool in reducing cancer’s global burden. COVID-19 showed the world that mRNA could be trusted. Cancer researchers are now seizing that momentum, pushing this technology beyond pandemics and into oncology. The promise is simple yet profound. Just as vaccines helped humanity control one of the greatest viral threats of our time, they might one day tame cancer itself.

Global Innovations:

The COVID-19 pandemic not only accelerated vaccine technology but also reshaped global biomedical innovation. Governments, research institutions, and pharmaceutical companies worldwide collaborated at an unprecedented scale, compressing years of development into months. This rapid progress showcased how mRNA platforms, AI-driven design, and advanced manufacturing could deliver effective vaccines quickly. Inspired by this success, scientists are now applying similar strategies to tackle cancer, aiming to create vaccines that are personalised, precise, and adaptive to each patient’s tumour profile. Across the United States, Europe, Japan, and emerging markets, research programs are leveraging genomic sequencing, computational biology, and lessons learned from COVID-19 to design next-generation cancer therapies. The pandemic demonstrated that accelerated, coordinated innovation is possible. This provides a blueprint for a new era in oncology where speed, personalisation, and collaboration can transform outcomes.

Moderna’s mRNA Cancer Vaccine: A Personalized Approach

Moderna, the American biotech giant best known for its COVID-19 vaccine, has been working quietly for years on cancer immunotherapy using the same mRNA platform. Unlike preventive vaccines that protect against viruses, Moderna’s cancer vaccines are designed as therapeutic vaccines. They do not prevent cancer from occurring, but instead train the immune system to recognise and destroy tumours that are already present. The concept is rooted in personalisation. Every patient’s tumour carries unique mutations known as neoantigens, genetic changes not found in healthy cells. Moderna’s scientists sequence a patient’s tumour DNA and use computational algorithms to identify the most promising neoantigens that could trigger an immune response. These selected targets are then encoded into strands of synthetic mRNA, which are packaged into lipid nanoparticles (the same delivery system used for the COVID-19 vaccine).

When injected, the mRNA instructs the body’s cells to produce fragments of these neoantigens. The immune system recognises them as “foreign” and generates T-cell responses specifically trained to attack tumour cells carrying those mutations. In effect, the patient receives a custom-made cancer vaccine designed from their own tumour profile. Their first randomised trial demonstrated that a personalised mRNA cancer vaccine can improve outcomes in humans, sparking enormous excitement in the oncology community. While melanoma is currently the leading focus, Moderna is expanding its pipeline to other difficult-to-treat cancers. Each vaccine is designed for the individual patient, meaning no two cancer vaccines are the same. Moderna has developed sophisticated AI-driven algorithms to rapidly analyse tumour genomes and design vaccine candidates within weeks, a speed unheard of in traditional cancer research.

mRNA vaccines offer several clear advantages. Their precision lies in targeting only cancer-specific mutations, sparing normal cells and reducing collateral damage. They are also highly adaptable, as tumours evolve and develop resistance, new vaccine doses can be reprogrammed to match emerging mutations. Another strength is their synergy with existing treatments. When combined with immunotherapies, mRNA vaccines can significantly amplify immune responses and improve outcomes. Finally, their safety profile is encouraging, with clinical trials so far reporting mostly mild flu-like symptoms, comparable to those seen with COVID-19 vaccines. Together, these features highlight why mRNA vaccines represent a breakthrough over traditional cancer therapies.

Despite the promising results, hurdles remain. Personalised vaccines require rapid sequencing, advanced computational modelling, and tailored manufacturing for each patient. These processes are complex and expensive. Moreover, large-scale Phase 3 trials are needed before regulatory approval can be granted. Still, Moderna’s progress represents a paradigm shift in oncology. Just as the company’s mRNA technology helped the world confront COVID-19, it may now help reimagine how we treat cancer—not with toxic chemotherapy, but with vaccines designed uniquely for every patient.

The global rush into personalised mRNA neoantigen vaccines after COVID-19 has influenced Japanese research, too. Japanese groups are exploring RNA-based designs (including self-amplifying mRNA constructs intended to improve durability and reduce dose) and building the bioinformatics and manufacturing capabilities required for personalised vaccines. However, as of now, most high-profile, late-stage mRNA cancer vaccine programs with randomised positive results have come from companies in the US and Europe (e.g., Moderna, BioNTech). Japan has strong capabilities and regulatory pathways, but it has not yet produced a late-stage, widely-approved mRNA cancer vaccine product. Across the globe, cancer vaccine research is progressing at an unprecedented pace. From Japan’s peptide-based and oncolytic virus therapies to Moderna’s personalised mRNA trials in the United States, and similar initiatives underway in Europe and China, scientists are exploring multiple strategies to train the immune system against tumours. These efforts highlight a shared ambition, to transform cancer treatment from broad, often toxic therapies to targeted, personalised interventions. Against this backdrop, Russia’s EnteroMix has grabbed headlines with claims of 100% efficacy and readiness for clinical use. While these announcements have generated excitement, experts caution that such claims are based on limited early-stage trials, and rigorous testing, long-term monitoring, and regulatory approval are still required. EnteroMix exemplifies both the hope and the uncertainty that currently define the global race to develop effective cancer vaccines, underscoring the innovation potential, while reminding us that scientific validation remains essential.

Role in Indian healthcare transformation:

From an Indian perspective, the global surge in cancer vaccine research presents both an opportunity and a challenge. India faces one of the highest cancer burdens in the world, with over 1.3 million new cases reported annually and limited access to advanced therapies in many regions. The rise of personalised mRNA vaccines and oncolytic therapies highlights the need for India to invest in biotechnology infrastructure, genomic sequencing capabilities, and regulatory frameworks that can support precision medicine. Collaborations with global leaders like Moderna, BioNTech, or even monitoring emerging products like Russia’s EnteroMix could allow Indian researchers and pharmaceutical companies to adapt these innovations for local populations, taking into account genetic diversity and regional cancer prevalence. Furthermore, leveraging India’s robust vaccine manufacturing ecosystem, which successfully scaled COVID-19 vaccines, could help develop affordable and accessible cancer vaccines, ensuring that breakthroughs in oncology benefit not only a few but the broader population.

To translate global advances into tangible benefits for India, several strategic steps can be considered. First, strengthening biotechnology infrastructure and expanding genomic sequencing facilities will enable the development of personalised cancer vaccines tailored to India’s diverse population. Second, public-private partnerships between government research institutes, hospitals, and pharmaceutical companies can accelerate clinical trials, regulatory approval, and local manufacturing. Third, investment in AI-driven drug and vaccine design can help rapidly identify neoantigens and optimise mRNA sequences, reducing both cost and development time. Fourth, India’s successful experience with mass vaccine production during COVID-19, as well as its proactive step of providing the HPV vaccine for free under national immunisation initiatives, demonstrates the country’s ability to implement large-scale preventive programs and offers a model for making future cancer vaccines accessible. Finally, creating regulatory pathways for fast-track approvals while maintaining safety standards will encourage innovation and attract global collaborations. With a high cancer burden, India can leverage its robust vaccine manufacturing infrastructure, ongoing HPV vaccination initiatives, and growing expertise in genomics and biotechnology to participate actively in this revolution. For India, this global momentum presents a unique opportunity. Strategic investments in personalised medicine, clinical trials, and AI-based vaccine design, combined with forward-looking regulatory frameworks, could ensure that India is not merely a recipient of these therapies but a significant contributor to global innovation.

Conclusion:

The global push for cancer vaccines, from Moderna’s personalised mRNA trials to Japan’s oncolytic therapies, and Russia’s EnteroMix illustrates a rapidly evolving landscape where innovation, speed, and precision medicine are redefining cancer treatment. While bold claims like those of EnteroMix capture headlines, the broader picture shows a measured but undeniable progress. Decades of immunotherapy research, lessons from COVID-19 mRNA vaccines, and advances in AI-driven personalised medicine are converging to make cancer vaccines a realistic possibility. Ultimately, the story of cancer vaccines, whether EnteroMix or mRNA platforms, is a story of hope tempered by scientific rigour. It underscores a universal truth: the fight against cancer requires global collaboration, meticulous research, and a commitment to translating breakthroughs into treatments that are both effective and accessible. As nations race toward personalised cancer therapies, India stands at the threshold of turning this challenge into an unprecedented opportunity to save lives and transform healthcare for millions.

. . .

Discus